An observational study in Genetic Health Risks, sponsored by Firalis SA. Completed at 2 sites in France. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-30.
Sponsored by Firalis SA · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 67 studies in Neurodegenerative Diseases with a site in France — 10 open to participants now, 16 under way, 1 of them phase 3. Neurodegenerative Diseases · France.
Among the 67 studies in Neurodegenerative Diseases with a site in France, this one is the 4th largest by enrollment of the 19 observational ones that give a count, is one of 4 that started in 2024, is one of 19 observational ones, and was the 56th registered.
436 studies on the registry are indexed under Neurodegenerative Diseases; 143 are open to participants now.
Browse Neurodegenerative Diseases studies →10 of the 67 studies in Neurodegenerative Diseases with a site in France are open now. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–90 · Healthy volunteers
GenSight Biologics · Sites in France
Ages 15+
MapLight Therapeutics · Sites in France, United States, Argentina and 12 more countries
Ages 55–90
University Hospital, Strasbourg, France · Sites in France
Ages 18+
Friedreich's Ataxia Research Alliance · Sites in France, United States, Australia and 14 more countries
Healthy volunteers
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 101 Neurodegenerative Diseases studies recruiting now, 52 (51%) set no upper age limit and 11 (11%) stop at 75 or younger; 20 take children under 18; 49 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
67 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 21 · Phase 3 17
First in 2002; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,474 is above the median of 186 across 156 observational studies indexed under Neurodegenerative Diseases.
Median enrollment 120 across the 48 interventional studies, 100 across the 19 observational. Of the 49 that completed or were terminated, 15 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
41 of 67 have an industry lead sponsor. The 10 most frequent:
Firalis SA is the lead sponsor of 7 studies on the registry; 3 are open to participants now.
Firalis SA has 1 study filed under Neurodegenerative Diseases — fewer than ten, so there is no comparison to draw.
2 of the studies in Neurodegenerative Diseases with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06185764Vertex Pharmaceuticals IncorporatedA Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) | 2027-02-02 |
| NCT06538974WandercraftAdherence to Long-term Exoskeleton Rehabilitation to Treat Lower Limb Weakness and / or Deficiencies in Adult Population | 2027-07-02 |
Add all 2 to your calendar (.ics) → With an account.
Among the 67 studies in Neurodegenerative Diseases with a site in France, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Firalis SA and its affiliate Amoneta Diagnostics SAS are developing novel in-vitro-diagnostic (IVD) tests for diverse diagnostic applications for major human diseases, including cardiovascular, and neurodegenerative disorders. These tests detect several gene mutations related to the above-mentioned pathologies. The development of IVD tools requires the evaluation of analytical parameters including biomarker stability.
The present specific study therefore aims to collect whole blood samples in PAXgene DNA tubes to complete the analytical validation of IVD tools and the evaluation of the stability of the DNA in PAXgene DNA tubes and the reagents in the IVD tools.
Healthy donors
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The cohort will be genotyped to determine the phenotype of the APOE allele
Diagnostic Test: APO-Easy
Testing for the APOE genotype using the APO-Easy Genotyping test
APOE Genotype
Blood samples will be collected to establish the feasibility of detecting several gene mutations associated with the risk of Alzheimer's disease/ Cardiovascular disorder and validation of analytical parameters
Time frame: Baseline
Specimen stability
Blood samples will be collected to establish the stability of PAXgene DNA samples at different timepoints after storage at -20° and -80°C.
Time frame: Baseline, 24hrs, 5 days, 28 days, 3 months, 12 months, 24 months
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Jan 2024 to primary completion in Mar 2025, 14 months.
Of 82 observational studies under Neurodegenerative Diseases, half reached primary completion within 94 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 216. This study's 14 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Firalis SA